

*Appln. Serial No. 10/567,737*  
*Amdt. Dated June 23, 2009*

- 2 -

**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A method of preventing or reducing neurological events in a subject comprising administering a therapeutically effective dosage of a glycosaminoglycan and a serpin to the subject to prevent or reduce the neurological events.
2. (Original) A method of claim 1 wherein the neurological event is associated with emboli.
3. (Original) A method of any preceding claim wherein the emboli are thromboemboli.
4. (Original) A method of any preceding claim wherein the serpin is antithrombin III.
5. (Original) A method of claim 4 wherein the antithrombin III is transgenic antithrombin III.
6. (Original) A method of any preceding claim wherein the glycosylaminoglycan is heparin or low molecular weight heparin.
7. (Currently Amended) A method of [any preceding] claim 1 wherein the glycosylaminoglycan and serpin form a complex or conjugate.
8. (Original) A method of claim 7 wherein the complex or conjugate comprises antithrombin III covalently linked to heparin.
9. (Original) A method of claim 8 wherein the complex or conjugate comprises ATH.
10. (Currently Amended) A method of [any preceding] claim 1 wherein the glycosaminoglycan and the serpin are administered prior to, during, or after a procedure that may give rise to a neurological event.

DOCS #478773 v. 1

*Appln. Serial No. 10/567,737*

*Amdt. Dated June 23, 2009*

- 3 -

11. (Original) A method of claim 10 wherein the procedure affects the central nervous system.
12. (Original) A method of claim 11 wherein the procedure affects the brain and/or cerebral circulation.
13. (Original) A method of claim 10 wherein the procedure is a surgical procedure.
14. (Original) A method of claim 13 wherein the procedure is cardiopulmonary bypass, cardiac catheterization, angioplasty, or endarterectomy.
15. (Original) A method as claimed in claim 2 comprising reducing emboli in the cerebral circulation in a subject comprising administering an amount of a glycosaminoglycan and a serpin effective to reduce the emboli.
16. (Currently Amended) A method of [any preceding] claim 15 for protecting a subject against cerebral embolization comprising administering an amount of a glycosaminoglycan and a serpin that reduces the amount of emboli that reach the cerebral vasculature.
17. (Currently Amended) A method of claim 13 wherein the surgical procedure is [performing] cardiac surgery and wherein [comprising administering] a therapeutically effective amount of a glycosaminoglycan and a serpin are administered peri-operatively to a subject undergoing cardiopulmonary bypass to prevent or reduce the effects of emboli.
18. (Original) A method of claim 2 comprising preventing or reducing emboli from a bypassed heart region prior to removal of the region from bypass by administering an amount of a glycosaminoglycan and a serpin effective to prevent or reduce the emboli.
19. (Currently Amended) A method of claim 2 wherein [using] a pharmaceutical composition comprising the glycosaminoglycan and the [a] serpin is administered to a subject to [in the

DOCS #478773 v. 1

*Appln. Serial No. 10/567,737*

*Amdt. Dated June 23, 2009*

- 4 -

preparation of a medicament for the] prevent[ion] or inhibit[ion of] cerebral embolization.

20. (Currently Amended) A method of claim 1 wherein [using] synergistically effective amounts of a glycosaminoglycan and a serpin are administered [in the preparation of a pharmaceutical composition for preventing or reducing neurological events].

21. (Currently Amended) A method of [any of] claim[s] 17 [17 to 20] wherein the glycosylaminoglycan and serpin form a complex or conjugate.

22. (Original) A method of claim 21 wherein the complex or conjugate comprises antithrombin III covalently linked to heparin.

23. (Original) A method of claim 21 wherein the complex or conjugate comprises ATH.

24. (Withdrawn) A pharmaceutical composition comprising a combination of a glycosaminoglycan and a serpin effective to exert a synergistic effect in preventing or reducing neurological events.

25. (Withdrawn) A pharmaceutical composition comprising a combination of a heparin or low molecular weight heparin and antithrombin III effective to in preventing or reducing neurological events.

DOCS #478773 v. 1